These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32112790)

  • 1. Twenty-year trends in the prescription costs of Type 2 diabetes: Real world data and empirical analysis in Greece.
    Athanasakis K; Prodromiadou E; Papazafiropoulou A; Koutsovasilis A; Driva S; Ziori M; Georgopoulos E; Gougourelas D; Sotiropoulos A; Bousboulas S; Melidonis A; Liatis S
    Diabetes Res Clin Pract; 2020 Apr; 162():108095. PubMed ID: 32112790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in the management of type 2 diabetes and its prescription drug costs in Greece (1998 & 2006).
    Liatis S; Thomakos P; Papaoikonomou S; Papazafeiropoulou A; Giannakopoulos N; Karagiaouri E; Sotiropoulos A; Bousboulas S; Melidonis A; Pappas S; Katsilambros N
    Exp Clin Endocrinol Diabetes; 2009 Oct; 117(9):505-10. PubMed ID: 19629932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
    Chirakup S; Chaiyakunapruk N; Chaikledkeaw U; Pongcharoensuk P; Ongphiphadhanakul B; Roze S; Valentine WJ; Palmer AJ
    Value Health; 2008 Mar; 11 Suppl 1():S43-51. PubMed ID: 18387067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
    Hansen RA; Farley JF; Droege M; Maciejewski ML
    Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.
    Caro JJ; Klittich WS; Raggio G; Kavanagh PL; O'Brien JA; Shomphe LA; Flegel KM; Copley-Merriman C; Sigler C
    Clin Ther; 2000 Jan; 22(1):116-27. PubMed ID: 10688395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in the prescription and cost of diabetic medications and monitoring equipment in England 1991-2004.
    Patel H; Srishanmuganathan J; Car J; Majeed A
    J Public Health (Oxf); 2007 Mar; 29(1):48-52. PubMed ID: 17124257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study.
    Suh HS; Kim JA; Lee IH
    BMC Health Serv Res; 2018 Jun; 18(1):429. PubMed ID: 29879966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug price, dosage and safety: Real-world evidence of oral hypoglycemic agents.
    Lin YS; Lin MT; Cheng SH
    Health Policy; 2019 Dec; 123(12):1221-1229. PubMed ID: 31466805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pattern of prescribing of glucose modulating agents for type 2 diabetes in general practices in England 2016/17.
    Heald AH; Livingston M; Bien Z; Moreno GYC; Laing I; Stedman M
    Int J Clin Pract; 2018 Apr; 72(4):e13080. PubMed ID: 29537664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan.
    Ou HT; Chen YT; Liu YM; Wu JS
    Diabetes Res Clin Pract; 2016 Jun; 116():14-25. PubMed ID: 27321311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004.
    Rathmann W; Haastert B; Icks A; Giani G
    Diabetes Care; 2007 Apr; 30(4):848-53. PubMed ID: 17392545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of initial antidiabetic agent and use of monitoring agents on prescription costs in newly treated type 2 diabetes: A retrospective cohort analysis.
    Grimes RT; Bennett K; Canavan R; Tilson L; Henman MC
    Diabetes Res Clin Pract; 2016 Mar; 113():152-9. PubMed ID: 26810270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in prescription use and spending for lipid-lowering and diabetes medications in the Veterans Affairs Healthcare System.
    Gellad WF; Good CB; Lowe JC; Donohue JM
    Am J Manag Care; 2010 Oct; 16(10):741-50. PubMed ID: 20964470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Sharing Rates Increase During Deep Recession: Preliminary Data From Greece.
    Gouvalas A; Igoumenidis M; Theodorou M; Athanasakis K
    Int J Health Policy Manag; 2016 May; 5(12):687-692. PubMed ID: 28005548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J; Torffvit O; Ridderstråle M; Ericsson Å; Nilsen B; Bøgelund M
    J Med Econ; 2012; 15 Suppl 2():1-5. PubMed ID: 22853443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL; Lloyd A; Best JH; DeYoung MB; Samyshkin Y; Gaebler JA
    J Med Econ; 2012; 15(4):654-63. PubMed ID: 22369345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K; Persson U
    J Med Econ; 2014 Sep; 17(9):658-69. PubMed ID: 24950434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis.
    Balkrishnan R; Rajagopalan R; Shenolikar RA; Camacho FT; Whitmire JT; Anderson RT
    Curr Med Res Opin; 2004 Oct; 20(10):1633-40. PubMed ID: 15462696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.